{"id":4275,"date":"2021-10-27T08:39:01","date_gmt":"2021-10-27T08:39:01","guid":{"rendered":"https:\/\/immunentech.com\/?page_id=4275"},"modified":"2022-03-22T14:27:59","modified_gmt":"2022-03-22T14:27:59","slug":"schwerpunkt-krebs","status":"publish","type":"page","link":"https:\/\/immunentech.com\/en\/schwerpunkt-krebs\/","title":{"rendered":"Schwerpunkt – Krebs"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Leber-, Kolon- und Lungenkrebs<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Entwicklung neuer Therapien f\u00fcr Leber-, Kolon- und Lungenkrebs<\/span><\/i><\/b><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Leber-, Kolon- und Lungenkrebs sind f\u00fcr mehr als f\u00fcnfzig Prozent aller neu diagnostizierten Krebserkrankungen verantwortlich. Etablierte Behandlungsmethoden wie Bestrahlung, Chemotherapie, zielgerichtete Therapien und Immun Checkpoint Inhibitoren sind anf\u00e4nglich wirksam, aber bei vielen Patienten kommt es zu Resistenzbildungen und zu progressiven Therapieversagen.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Entwicklung und klinische Translation<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Eines der wesentlichen Ziele von ImmuneNTech ist die Entwicklung und klinische Translation von effizienten Therapien f\u00fcr diese Krebstypen. ImmuneNTech hat eine neuartige Krebsimmuntherapie (INT-T12) entwickelt, welche hochwirksam und signifikant besser als Checkpoint-Inhibitor Therapien ist. INT-T12 erweitert und verbessert damit die therapeutische Wirksamkeit der zuvor von uns in der Universit\u00e4tsmedizin Mainz entwickelten Therapy-X*<\/span>.<\/span><\/p>

Die erste klinische Validierung von INT-T12 bei Lungenkrebspatienten ist f\u00fcr das Jahr 2023-24 geplant.<\/span><\/p>

\u00a0<\/span><\/p>

* Therapy-X: A pharmaceutical combination for the use in the treatment of cancer; Europ\u00e4isches Patentamt PCT\/EP2019\/061683<\/a><\/span><\/strong><\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Fatigue-Syndrom und long-COVID<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fatigue-Syndrom, als Form einer chronischen Erm\u00fcdung basiert ebenso wie das long-COVID Syndrom auf einer schweren Sch\u00e4digung der Mitochondrien (mitochondriale Damage) infolge einer chronischen Unterversorgung mit Sauerstoff.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tMehr erfahren zu Fatigue-Syndrom und long-COVID >><\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Kontakt<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Haben wir Ihr Interesse geweckt? Kontaktieren Sie uns gerne telefonisch oder \u00fcber das Kontaktformular.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tZu den Kontaktdaten >><\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Leber-, Kolon- und Lungenkrebs Entwicklung neuer Therapien f\u00fcr Leber-, Kolon- und Lungenkrebs Leber-, Kolon- und Lungenkrebs sind f\u00fcr mehr als f\u00fcnfzig Prozent […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-4275","page","type-page","status-publish","hentry"],"yoast_head":"\nSchwerpunkt - Krebs - ImmuneNTech GmbH<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Schwerpunkt - Krebs - ImmuneNTech GmbH\" \/>\n<meta property=\"og:description\" content=\"Leber-, Kolon- und Lungenkrebs Entwicklung neuer Therapien f\u00fcr Leber-, Kolon- und Lungenkrebs Leber-, Kolon- und Lungenkrebs sind f\u00fcr mehr als f\u00fcnfzig Prozent […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/immunentech.com\/en\/schwerpunkt-krebs\/\" \/>\n<meta property=\"og:site_name\" content=\"ImmuneNTech GmbH\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-22T14:27:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/immunentech.com\/wp-content\/uploads\/2022\/03\/Doctor-mit-jungen-Frau-1024x683.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/\",\"url\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/\",\"name\":\"Schwerpunkt - Krebs - ImmuneNTech GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/immunentech.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/immunentech.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Doctor-mit-jungen-Frau-1024x683.jpg\",\"datePublished\":\"2021-10-27T08:39:01+00:00\",\"dateModified\":\"2022-03-22T14:27:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/immunentech.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Doctor-mit-jungen-Frau-1024x683.jpg\",\"contentUrl\":\"https:\\\/\\\/immunentech.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Doctor-mit-jungen-Frau-1024x683.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/immunentech.com\\\/schwerpunkt-krebs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/immunentech.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Schwerpunkt – Krebs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/immunentech.com\\\/#website\",\"url\":\"https:\\\/\\\/immunentech.com\\\/\",\"name\":\"ImmuneNTech GmbH\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/immunentech.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Schwerpunkt - Krebs - ImmuneNTech GmbH","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_GB","og_type":"article","og_title":"Schwerpunkt - Krebs - ImmuneNTech GmbH","og_description":"Leber-, Kolon- und Lungenkrebs Entwicklung neuer Therapien f\u00fcr Leber-, Kolon- und Lungenkrebs Leber-, Kolon- und Lungenkrebs sind f\u00fcr mehr als f\u00fcnfzig Prozent […]","og_url":"https:\/\/immunentech.com\/en\/schwerpunkt-krebs\/","og_site_name":"ImmuneNTech GmbH","article_modified_time":"2022-03-22T14:27:59+00:00","og_image":[{"url":"https:\/\/immunentech.com\/wp-content\/uploads\/2022\/03\/Doctor-mit-jungen-Frau-1024x683.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/immunentech.com\/schwerpunkt-krebs\/","url":"https:\/\/immunentech.com\/schwerpunkt-krebs\/","name":"Schwerpunkt - Krebs - ImmuneNTech GmbH","isPartOf":{"@id":"https:\/\/immunentech.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/immunentech.com\/schwerpunkt-krebs\/#primaryimage"},"image":{"@id":"https:\/\/immunentech.com\/schwerpunkt-krebs\/#primaryimage"},"thumbnailUrl":"https:\/\/immunentech.com\/wp-content\/uploads\/2022\/03\/Doctor-mit-jungen-Frau-1024x683.jpg","datePublished":"2021-10-27T08:39:01+00:00","dateModified":"2022-03-22T14:27:59+00:00","breadcrumb":{"@id":"https:\/\/immunentech.com\/schwerpunkt-krebs\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/immunentech.com\/schwerpunkt-krebs\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/immunentech.com\/schwerpunkt-krebs\/#primaryimage","url":"https:\/\/immunentech.com\/wp-content\/uploads\/2022\/03\/Doctor-mit-jungen-Frau-1024x683.jpg","contentUrl":"https:\/\/immunentech.com\/wp-content\/uploads\/2022\/03\/Doctor-mit-jungen-Frau-1024x683.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/immunentech.com\/schwerpunkt-krebs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/immunentech.com\/"},{"@type":"ListItem","position":2,"name":"Schwerpunkt – Krebs"}]},{"@type":"WebSite","@id":"https:\/\/immunentech.com\/#website","url":"https:\/\/immunentech.com\/","name":"ImmuneNTech GmbH","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/immunentech.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/pages\/4275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/comments?post=4275"}],"version-history":[{"count":91,"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/pages\/4275\/revisions"}],"predecessor-version":[{"id":5871,"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/pages\/4275\/revisions\/5871"}],"wp:attachment":[{"href":"https:\/\/immunentech.com\/en\/wp-json\/wp\/v2\/media?parent=4275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}